Filed by Mylan N.V.
Pursuant to Rule 425 under the Securities Act of 1933
and deemed filed pursuant to Rule 14a-12
under the Securities Exchange Act of 1934
Subject Company: Mylan N.V.
Commission File No.: 333-199861
Mylan and Pfizer Announce Viatris as the New Company Name in the Planned Mylan-Upjohn Combination
HERTFORDSHIRE, England, PITTSBURGH and NEW YORK, Nov. 12, 2019 Mylan N.V. (NASDAQ: MYL) and Pfizer Inc. (NYSE: PFE) today announced that the name of
the new company to be formed by the planned combination of Mylan and Upjohn, a division of Pfizer, will be Viatris (pronounced viǝ-trīs).
Deriving its name from Latin, Viatris embodies the new companys goal of providing a pathVIAto
threeTRIScore goals: expanding access to medicines, leading by innovating to meet patient needs, and being a trusted partner for the healthcare community worldwide.
We wanted a name that would differentiate our new company and clearly explain how we will be a champion for global health, said Robert J. Coury,
who will serve as Executive Chairman of the new company, as previously announced. We are creating a company unlike any other a company focused on building a more hopeful and sustainable healthcare journey, empowering patients to live
healthier at every stage of life.
The name Viatris communicates the strength of our companies combined heritage and our shared goal to
provide the highest-quality medicines to the most patients possible, said Michael Goettler, Group President, Upjohn, who will serve as Chief Executive Officer of Viatris, as previously announced. We have an opportunity to deliver better
health, better care and better value for patients and partners around the world.
Formed through a combination of two highly complementary
businesses, Viatris will unite Upjohns strong leadership position in China and emerging markets with Mylans significant presence in the U.S. and Europe, allowing the new company to have a meaningfully expanded geographic reach for
Viatris broad product portfolio and future pipeline.
It is expected that in the coming months, shareholders of Mylan will vote on the proposed
combination of Mylan and Upjohn. More information regarding Viatris, including the companys full executive management team, board of directors, stock symbol, and logo will be available at a later date.
Customers and patients will continue to be served by the Mylan and Upjohn brands for the near future. The new name will be effective upon closing of the
combination, which is expected to occur in mid-2020. The two companies will continue to operate as independent, separate organizations until close.